Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting –December 14, 2011 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
   A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
   A. November 9, 2011 DUR Minutes – Vote
   B. November 10, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
   A. Retrospective Drug Utilization Review for August 2011
   B. Retrospective Drug Utilization Review Response for July 2011
   C. Medication Coverage Activity Audit for November 2011
   D. Pharmacy Help Desk Activity Audit for November 2011

Items to be presented by Mr. Kimble, Dr. Muchmore, Chairman

5. **Overview of OHCA Advisory Groups**

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

6. **Action Item – Vote on 2012 Meeting Dates – See Appendix C.**

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Multiple Sclerosis Medications – See Appendix D.**
   A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Vote to Prior Authorize Daliresp® – See Appendix E.**
   A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

9. **Action Item – Vote to Prior Horizant® – See Appendix F.**
   A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. **Action Item – Vote to Prior Authorize Gralise™ – See Appendix G.**
    A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

11. **Action Item – Annual Review of Antihistamines – See Appendix H.**
    A. Current Authorization Criteria
    B. Utilization Review
    C. Prior Authorization Review
    D. Market News and Update
    E. COP Recommendations
    F. Utilization Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

12. **Action Item – Annual Review of Statin and Statin Combination Products – See Appendix I.**
    A. Current Authorization Criteria
    B. Utilization Review
    C. Prior Authorization Review
    D. Market News and Update
    E. COP Recommendations
    F. Utilization Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

13. **Action Item – Annual Review of Lovaza® – See Appendix J.**
    A. Current Authorization Criteria
    B. Utilization Review
    C. Prior Authorization Review
    D. COP Recommendations

Items to be presented by Dr. Le, Dr. Keast, Dr. Muchmore, Chairman

14. **30 Day Notice to Prior Authorize Brilinta™ and Xarelto™ – See Appendix K.**
    A. Brilinta™
    B. Xarelto™

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

15. FDA and DEA Updates – See Appendix L.

16. Future Business

A. Annual Review of Narcotics
B. Annual Review of Ribavirin
C. New Product Reviews
D. Medical Product Reviews

17. Adjournment